Advancing Novel Treatments for Endocrine Disorders

Spruce is building a sustainable pipeline of treatments for patients suffering from rare endocrine disorders. Our portfolio includes first- and best-in-class small molecules.

Now Enrolling

Congenital Adrenal Hyperplasia Clinical Trials 2017

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new therapy for CAH. Take our prescreened to see if you may qualify at www.CAHclinicaltrial.com

Learn More

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.